EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2022
TABLES
122
PAGES
196
EDITION
18
PRICE
USD 5600
CODE
MCP-1205
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
SELECT PLAYERS
Abbott India Limited; Aspen Holdings; Bayer Healthcare AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; Mitsubishi Tanabe Pharma Corp.; Pfizer Inc.; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Drug Class (NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist, Other Drug Classes) » Route of Administration (Oral Anticoagulant, Injectable Anticoagulant) » Application (Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Other Applications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Venous ThromboEmbolism (VTE) - A Prelude |
Recent Market Activity |
Anticoagulants Market Driven by Novel Oral Anti-coagulants |
Sizing the Market |
Safety Issues Associated with Erstwhile Market Leaders - Warfarin & Heparins |
Anticoagulants - Evolution from Injectables to Oral Drugs |
Conventional Oral Drug - Warfarin - Face the Heat |
The Newer Breed of NOACs |
Comparative Analysis of Warfarin and Novel Oral Anticoagulants |
Bevyxxa (Betrixaban) - The Latest Approved NOAC |
Aging Population: A Crucial Driver for Anticoagulants Market |
Global Menace of Cardiovascular Disease - A Major Growth Factor |
Increasing Prevalence of AF Impacts Growth Prospects |
Rising Stroke Statistics - An Opportunity Indicator for Anticoagulants |
Increasing Incidence of Knee/Hip Replacement Surgeries Drive Market Growth |
Increasing Healthcare Spending in Emerging Markets |
Adverse Effects: A Key Market Deterrent |
Common Adverse Effects of NOAC Therapies |
Increased Bleeding - A Major Concern with Newer Agents |
Novel Oral Drugs: Absence of Antidote & Other Concerns |
US FDA Delays Andexxa (the Xarelto and Eliquis Antidote) Approval |
Reversal Agents for DOACs |
Threat of Generics Looms Large on the Anti-Coagulants Market |
Patent Expiries of Oral Anticoagulants |
Pipeline Analysis |
Tecarfarin (Espero BioPharma) |
List of Ongoing NOAC Studies |
Anticoagulants – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
2. FOCUS ON SELECT PLAYERS |
Abbott India Limited (India) |
Aspen Holdings (South Africa) |
Bayer AG (Germany) |
Boehringer Ingelheim (Germany) |
Bristol-Myers Squibb Company (USA) |
Mitsubishi Tanabe Pharma Corporation (Japan) |
Pfizer, Inc. (USA) |
Sanofi S.A. (France) |
Teva Pharmaceutical Industries Ltd. (Israel) |
3. MARKET TRENDS & DRIVERS |
NOACs to Emerge as Mainstream Option for VTE Patients |
NICE Guidelines Promote NOAC Usage in Atrial Fibrillation |
NOACs as Alternative/Supplement to Antiplatelet Therapy |
Increase in Heparin Trade Boosts the Market |
Modern Developments Improving Anticoagulation Management |
Researchers Find Significant Correlation between NAOC and Newer Health Risks |
NOAC Underdosing Trend Restrains Universal Acceptance |
Underutilization of Oral Anticoagulants in Atrial Fibrillation |
Generics Prevail in the Traditional Market |
Patent Expiries of Traditional Anticoagulants in the US |
Inadequate Trials Mar Pediatric Anticoagulants Market |
New Advancements Improve Anticoagulation Management |
Growing Demand for Self-Testing |
LMWHs Ease Outpatient Management |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for NOACs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for NOACs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for NOACs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Xarelto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Xarelto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Xarelto by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Heparin & LMWH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Heparin & LMWH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Heparin & LMWH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Vitamin K Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Vitamin K Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Vitamin K Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Oral Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Oral Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Oral Anticoagulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Injectable Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Injectable Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Injectable Anticoagulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Pulmonary Embolism (PE) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
JAPAN |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
CHINA |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
China Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
China Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
EUROPE |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Anticoagulants by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
FRANCE |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
France Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
France Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
GERMANY |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
UNITED KINGDOM |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Spain Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Spain Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Russia Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Russia Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
ASIA-PACIFIC |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Anticoagulants by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
AUSTRALIA |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
Australia Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Australia Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Australia Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
INDIA |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
India Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
India Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
India Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
India Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
India Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
India Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
South Korea Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
South Korea Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
LATIN AMERICA |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
Latin America Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Anticoagulants by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Argentina Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Argentina Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Brazil Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Brazil Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Mexico Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Mexico Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Rest of Latin America Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Rest of Latin America Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
MIDDLE EAST |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
Middle East Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Anticoagulants by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
IRAN |
Iran Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Iran Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Iran Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Israel Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Israel Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Saudi Arabia Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Saudi Arabia Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
UAE Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
UAE Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Rest of Middle East Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Rest of Middle East Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
AFRICA |
Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
Africa Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2012, 2021 & 2027 |
Africa Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2012, 2021 & 2027 |
Africa Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2012, 2021 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 48 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com